Advertisement

Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: A systematic review and meta-analysis of randomized controlled trials

Published:August 13, 2022DOI:https://doi.org/10.1016/j.jiac.2022.08.008

      Abstract

      Background

      Fidaxomicin (FDX) has received considerable attention as a novel therapeutic alternative agent to vancomycin (VCM) for Clostridioides difficile infection (CDI). However, the superiority and efficacy profile of FDX are not sufficiently determined by high-quality evidence. This study aimed to clarify the superiority of FDX for CDI treatment through a systematic review and meta-analysis.

      Methods

      We conducted a meta-analysis of randomized controlled trials (RCTs) which evaluated the efficacy and safety of FDX and VCM in patients with CDI. Electronic databases (PubMed, Cochrane Library, Web of Science, and Clinicaltrials.gov) were searched for studies published until October 15, 2021. The primary endpoint was global cure. The secondary endpoints were clinical cure, recurrence, and adverse event. Risk ratios (RRs), risk differences (RDs), and 95% confidence intervals were calculated using Mantel-Haenszel random-effects model. The risk of bias was assessed using Cochrane Handbook for Systematic Reviews of Interventions and Assessment Criteria.

      Results

      Six RCTs were included in this meta-analysis. Compared to VCM, FDX was associated with significantly higher global cure rates (RR = 1.18, P < 0.00001; RD = 0.11, 95% CI = 0.07–0.16). In addition, clinical cure rates were comparable between FDX and VCM (P = 0.31). FDX was associated with significantly lower recurrence rates compared to VCM (RR = 0.59, P < 0.0001). In addition, adverse event rates were not significantly different between the drugs (P = 0.41).

      Conclusion

      FDX achieves significantly higher global cure rates and lower recurrence rates and is comparable to VCM in clinical cure rates and adverse event rates in patients with CDI. Collectively, FDX is superior to VCM as a therapeutic agent for CDI.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Infection and Chemotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Usui M.
        One health approach to Clostridioides difficile in Japan.
        J Infect Chemother. 2020; 26: 643-650https://doi.org/10.1016/j.jiac.2020.03.012
        • Mullish B.H.
        • Williams H.R.T.
        Clostridium difficile infection and antibiotic-associated diarrhoea.
        Clin Med J R Coll Physicians London. 2018; 18: 237-241https://doi.org/10.7861/clinmedicine.18-3-237
        • CDC
        Antibiotic resistance threats in the United States, 2019.
        U.S. Department of Health and Human Services, CDC, Atlanta, GA2019
        • Thomas C.
        • Stevenson M.
        • Riley T.V.
        Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review.
        J Antimicrob Chemother. 2003; 51: 1339-1350https://doi.org/10.1093/jac/dkg254
        • Deshpande A.
        • Pasupuleti V.
        • Thota P.
        • Pant C.
        • Rolston D.D.K.
        • Sferra T.J.
        • et al.
        Community-associated clostridium difficile infection antibiotics: a meta-analysis.
        J Antimicrob Chemother. 2013; 68: 1951-1961https://doi.org/10.1093/jac/dkt129
        • Slimings C.
        • Riley T.V.
        Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis.
        J Antimicrob Chemother. 2014; 69: 881-891https://doi.org/10.1093/jac/dkt477
        • Vardakas K.Z.
        • Trigkidis K.K.
        • Boukouvala E.
        • Falagas M.E.
        Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis.
        Int J Antimicrob Agents. 2016; 48: 1-10https://doi.org/10.1016/j.ijantimicag.2016.03.008
        • Eze P.
        • Balsells E.
        • Kyaw M.H.
        • Nair H.
        Risk factors for Clostridium difficile infections - an overview of the evidence base and challenges in data synthesis.
        J Glob Health. 2017; 7010417https://doi.org/10.7189/jogh.07.010417
        • Rupnik M.
        • Wilcox M.H.
        • Gerding D.N.
        Clostridium difficile infection: new developments in epidemiology and pathogenesis.
        Nat Rev Microbiol. 2009; 7: 526-536https://doi.org/10.1038/nrmicro2164
        • Garey K.W.
        • Sethi S.
        • Yadav Y.
        • DuPont H.L.
        Meta-analysis to assess risk factors for recurrent Clostridium difficile infection.
        J Hosp Infect. 2008; 70: 298-304https://doi.org/10.1016/j.jhin.2008.08.012
        • Thongprayoon C.
        • Cheungpasitporn W.
        • Phatharacharukul P.
        • Edmonds P.J.
        • Kaewpoowat Q.
        • Mahaparn P.
        • et al.
        Chronic kidney disease and end-stage renal disease are risk factors for poor outcomes of Clostridium difficile infection: a systematic review and meta-analysis.
        Int J Clin Pract. 2015; 69: 998-1006https://doi.org/10.1111/ijcp.12672
        • Crook D.W.
        • Sarah Walker A.
        • Kean Y.
        • Weiss K.
        • Cornely O.A.
        • Miller M.A.
        • et al.
        Fidaxomicin versus vancomycin for clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.
        Clin Infect Dis. 2012; 55: S93-S103https://doi.org/10.1093/cid/cis499
        • Oshima T.
        • Wu L.
        • Li M.
        • Fukui H.
        • Watari J.
        • Miwa H.
        Magnitude and direction of the association between Clostridium difficile infection and proton pump inhibitors in adults and pediatric patients: a systematic review and meta-analysis.
        J Gastroenterol. 2018; 53: 84-94https://doi.org/10.1007/s00535-017-1369-3
        • Musher D.M.
        • Aslam S.
        • Logan N.
        • Nallacheru S.
        • Bhaila I.
        • Borchert F.
        • et al.
        Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole.
        Clin Infect Dis. 2005; 40: 1586-1590https://doi.org/10.1086/430311
        • Pépin J.
        • Routhier S.
        • Gagnon S.
        • Brazeau I.
        Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada.
        Clin Infect Dis. 2006; 42: 758-764https://doi.org/10.1086/501126
        • Johnson S.
        Recurrent Clostridium difficile infection: causality and therapeutic approaches.
        Int J Antimicrob Agents. 2009; 33: S33-S36https://doi.org/10.1016/S0924-8579(09)70014-7
        • Figueroa I.
        • Johnson S.
        • Sambol S.P.
        • Goldstein E.J.C.
        • Citron D.M.
        • Gerding D.N.
        Relapse versus reinfection: recurrent clostridium difficile infection following treatment with fidaxomicin or vancomycin.
        Clin Infect Dis. 2012; 55: S104-S109https://doi.org/10.1093/cid/cis357
        • Abou Chakra C.N.
        • Pepin J.
        • Sirard S.
        • Valiquette L.
        Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review.
        PLoS One. 2014; 9e98400https://doi.org/10.1371/journal.pone.0098400
        • Sheitoyan-Pesant C.
        • Abou Chakra C.N.
        • Pépin J.
        • Marcil-Héguy A.
        • Nault V.
        • Valiquette L.
        Clinical and healthcare burden of multiple recurrences of Clostridium difficile infection.
        Clin Infect Dis. 2016; 62: 574-580https://doi.org/10.1093/cid/civ958
        • Mcfarland L.V.
        • Surawicz C.M.
        • Elmer G.W.
        • Moyer K.A.
        • Melcher S.A.
        • Fekety R.
        • et al.
        A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease.
        JAMA, J Am Med Assoc. 1994; 271: 1913-1918https://doi.org/10.1001/jama.1994.03510480037031
        • McFarland L.V.
        • Elmer G.W.
        • Surawicz C.M.
        Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease.
        Am J Gastroenterol. 2002; 97: 1769-1775https://doi.org/10.1016/S0002-9270(02)04195-3
        • Gupta A.
        • Ananthakrishnan A.N.
        Economic burden and cost-effectiveness of therapies for Clostridiodes difficile infection: a narrative review.
        Therap Adv Gastroenterol. 2021; 1417562848211018654https://doi.org/10.1177/17562848211018654
        • Li R.
        • Lu L.
        • Lin Y.
        • Wang M.
        • Liu X.
        Efficacy and safety of metronidazole monotherapy versus vancomycin monotherapy or combination therapy in patients with clostridium difficile infection: a systematic review and meta-analysis.
        PLoS One. 2015; 10e0137252https://doi.org/10.1371/journal.pone.0137252
        • Igarashi Y.
        • Tashiro S.
        • Enoki Y.
        • Taguchi K.
        • Matsumoto K.
        • Ohge H.
        • et al.
        Oral vancomycin versus metronidazole for the treatment of Clostridioides difficile infection: meta-analysis of randomized controlled trials.
        J Infect Chemother. 2018; 24: 907-914https://doi.org/10.1016/j.jiac.2018.08.003
        • Tomas M.E.
        • Mana T.S.C.
        • Wilson B.M.
        • Nerandzic M.M.
        • Joussef-Piña S.
        • Quiñones-Mateu M.E.
        • et al.
        Tapering courses of oral vancomycin induce persistent disruption of the microbiota that provide colonization resistance to Clostridium difficile and vancomycin-resistant Enterococci in mice.
        Antimicrob Agents Chemother. 2018; 62: 1-9https://doi.org/10.1128/aac.02237-17
        • van Prehn J.
        • Reigadas E.
        • Vogelzang E.H.
        • Bouza E.
        • Hristea A.
        • Guery B.
        • et al.
        European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.
        Clin Microbiol Infect. 2021; 27: S1-S21https://doi.org/10.1016/j.cmi.2021.09.038
        • Löfmark S.
        • Edlund C.
        • Nord C.E.
        Metronidazole is still the drug of choice for treatment of anaerobic infections.
        Clin Infect Dis. 2010; 50: S16-S23https://doi.org/10.1086/647939
        • Kunishima H.
        • Ohge H.
        • Suzuki H.
        • Nakamura A.
        Japanese clinical practice guidelines for management of Clostridioides (Clostridium) difficile infection.
        J Infect Chemother:accepted. 13 Dec 2021; https://doi.org/10.1016/j.jiac.2021.12.011
        • Johnson S.
        • Lavergne V.
        • Skinner A.M.
        • Gonzales-Luna A.J.
        • Garey K.W.
        • Kelly C.P.
        • et al.
        Clinical practice guideline by the infectious diseases society of America (IDSA) and society for healthcare epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults.
        Clin Infect Dis. 2021; 73: e1029-e1044https://doi.org/10.1093/cid/ciab549
        • Kelly C.R.
        • Fischer M.
        • Allegretti J.R.
        • LaPlante K.
        • Stewart D.B.
        • Limketkai B.N.
        • et al.
        ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections.
        Am J Gastroenterol. 2021; 116: 1124-1147https://doi.org/10.14309/ajg.0000000000001278
        • Louie T.J.
        • Miller M.A.
        • Mullane K.M.
        • Weiss K.
        • Lentnek A.
        • Golan Y.
        • et al.
        Fidaxomicin versus vancomycin for Clostridium difficile infection.
        N Engl J Med. 2011; 364: 422-431https://doi.org/10.1056/nejmoa0910812
        • Cornely O.A.
        • Crook D.W.
        • Esposito R.
        • Poirier A.
        • Somero M.S.
        • Weiss K.
        • et al.
        Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
        Lancet Infect Dis. 2012; 12: 281-289https://doi.org/10.1016/S1473-3099(11)70374-7
        • Page M.J.
        • McKenzie J.E.
        • Bossuyt P.M.
        • Boutron I.
        • Hoffmann T.C.
        • Mulrow C.D.
        • et al.
        The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
        BMJ. 2021; 372: n71https://doi.org/10.1136/bmj.n71
        • Higgins J.
        • Green S.
        Cochrane handbook for systematic reviews of interventions version 5.1.0.
        Cochrane Collab, 2011 ([updated March 2011])
        • Housman S.T.
        • Thabit A.K.
        • Kuti J.L.
        • Quintiliani R.
        • Nicolau D.P.
        Assessment of Clostridium difficile burden in patients over time with first episode infection following fidaxomicin or vancomycin.
        Infect Control Hosp Epidemiol. 2016; 37: 215-218https://doi.org/10.1017/ice.2015.270
        • Thabit A.K.
        • Alam M.J.
        • Khaleduzzaman M.
        • Garey K.W.
        • Nicolau D.P.
        A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin.
        Ann Clin Microbiol Antimicrob. 2016; 15: 22https://doi.org/10.1186/s12941-016-0140-6
        • Mikamo H.
        • Tateda K.
        • Yanagihara K.
        • Kusachi S.
        • Takesue Y.
        • Miki T.
        • et al.
        Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
        J Infect Chemother. 2018; 24: 744-752https://doi.org/10.1016/j.jiac.2018.05.010
        • Hvas C.L.
        • Dahl Jørgensen S.M.
        • Jørgensen S.P.
        • Storgaard M.
        • Lemming L.
        • Hansen M.M.
        • et al.
        Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection.
        Gastroenterology. 2019; 156 (e3): 1324-1332https://doi.org/10.1053/j.gastro.2018.12.019
        • Ajami N.J.
        • Cope J.L.
        • Wong M.C.
        • Petrosino J.F.
        • Chesnel L.
        Impact of oral fidaxomicin administration on the intestinal microbiota and susceptibility to clostridium difficile colonization in mice.
        Antimicrob Agents Chemother. 2018; 62e02112-e02117https://doi.org/10.1128/AAC.02112-17
        • Louie T.J.
        • Cannon K.
        • Byrne B.
        • Emery J.
        • Ward L.
        • Eyben M.
        • et al.
        Fidaxomicin preserves the intestinal microbiome during and after treatment of clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
        Clin Infect Dis. 2012; 55: 132-142https://doi.org/10.1093/cid/cis338
        • Babakhani F.
        • Gomez A.
        • Robert N.
        • Sears P.
        Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.
        J Med Microbiol. 2011; 60: 1213-1217https://doi.org/10.1099/jmm.0.029470-0
        • Babakhani F.
        • Gomez A.
        • Robert N.
        • Sears P.
        Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.
        Antimicrob Agents Chemother. 2011; 55: 4427-4429https://doi.org/10.1128/AAC.00104-11
        • Babakhani F.
        • Bouillaut L.
        • Gomez A.
        • Sears P.
        • Nguyen L.
        • Sonenshein A.L.
        Fidaxomicin inhibits spore production in clostridium difficile.
        Clin Infect Dis. 2012; 55: S162-S169https://doi.org/10.1093/cid/cis453
        • Srikhanta Y.N.
        • Hutton M.L.
        • Awad M.M.
        • Drinkwater N.
        • Singleton J.
        • Day S.L.
        • et al.
        Cephamycins inhibit pathogen sporulation and effectively treat recurrent Clostridioides difficile infection.
        Nat Microbiol. 2019; 4: 2237-2245https://doi.org/10.1038/s41564-019-0519-1
        • Castro-Córdova P.
        • Mora-Uribe P.
        • Reyes-Ramírez R.
        • Cofré-Araneda G.
        • Orozco-Aguilar J.
        • Brito-Silva C.
        • et al.
        Entry of spores into intestinal epithelial cells contributes to recurrence of Clostridioides difficile infection.
        Nat Commun. 2021; 12: 1140https://doi.org/10.1038/s41467-021-21355-5
        • Koon H.W.
        • Wang J.
        • Mussatto C.C.
        • Ortiz C.
        • Lee E.C.
        • Tran D.H.N.
        • et al.
        Fidaxomicin and OP-1118 inhibit Clostridium difficile toxin A- and B-mediated inflammatory responses via inhibition of NF-κB activity.
        Antimicrob Agents Chemother. 2018; 62e01513-e01517https://doi.org/10.1128/AAC.01513-17
        • Park S.W.
        • Choi A.R.
        • Lee H.J.
        • Chung H.
        • Park J.C.
        • Shin S.K.
        • et al.
        The effects of statins on the clinical outcomes of Clostridium difficile infection in hospitalised patients.
        Aliment Pharmacol Ther. 2013; 38: 619-627https://doi.org/10.1111/apt.12439
        • Saliba W.
        • Barnett-Griness O.
        • Elias M.
        • Rennert G.
        Statins use and risk of mortality in patient with Clostridium difficile infection.
        Clin Microbiol Infect. 2014; 20: 1061-1066https://doi.org/10.1111/1469-0691.12672
        • Biggs M.
        • Iqbal T.
        • Holden E.
        • Clewer V.
        • Garvey M.I.
        Effect of using fidaxomicin on recurrent Clostridium difficile infection.
        J Hosp Infect. 2019; 102: 165-167https://doi.org/10.1016/j.jhin.2018.12.018
        • Polivkova S.
        • Krutova M.
        • Capek V.
        • Sykorova B.
        • Benes J.
        Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection — an observational cohort study.
        Int J Infect Dis. 2021; 103: 226-233https://doi.org/10.1016/j.ijid.2020.11.004
        • Summers B.B.
        • Yates M.
        • Cleveland K.O.
        • Gelfand M.S.
        • Usery J.
        Fidaxomicin compared with oral vancomycin for the treatment of severe Clostridium difficile–associated diarrhea: a retrospective review.
        Hosp Pharm. 2020; 55: 268-272https://doi.org/10.1177/0018578719844165